INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30131% above fair value
$141.33−3.13 (-2.17%)
Close on Nov 20, 2026Market cap $31.01BP/E –Yield –
Insmed gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Insmed's gross profit for the twelve months ending Sep 30, 2026 was $1.28B, up 274.9% year over year. For fiscal 2025 it was $483.49M, up 73.9% from the year before. The highest annual figure on record is $483.49M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $483.49M | +73.9% |
| FY2024 | Dec 31, 2024 | $277.97M | +16.0% |
| FY2023 | Dec 31, 2023 | $239.64M | +26.0% |
| FY2022 | Dec 31, 2022 | $190.23M | +31.8% |
| FY2021 | Dec 31, 2021 | $144.31M | +15.9% |
| FY2020 | Dec 31, 2020 | $124.54M | +10.9% |
| FY2019 | Dec 31, 2019 | $112.26M | +1414.5% |
| FY2018 | Dec 31, 2018 | $7.41M | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $446.21M | +295.0% |
| Q2 FY2026 | Jun 30, 2026 | $358.27M | +351.6% |
| Q1 FY2026 | Mar 31, 2026 | $258.54M | +261.4% |
| Q4 FY2025 | Dec 31, 2025 | $219.62M | +180.5% |
| Q3 FY2025 | Sep 30, 2025 | $112.98M | +56.4% |
| Q2 FY2025 | Jun 30, 2025 | $79.34M | +14.4% |
| Q1 FY2025 | Mar 31, 2025 | $71.55M | +23.3% |
| Q4 FY2024 | Dec 31, 2024 | $78.29M | +20.0% |
| Q3 FY2024 | Sep 30, 2024 | $72.26M | +15.9% |
| Q2 FY2024 | Jun 30, 2024 | $69.38M | +14.4% |
| Q1 FY2024 | Mar 31, 2024 | $58.04M | +13.0% |
| Q4 FY2023 | Dec 31, 2023 | $65.25M | +41.1% |
| Q3 FY2023 | Sep 30, 2023 | $62.37M | +14.9% |
| Q2 FY2023 | Jun 30, 2023 | $60.64M | +24.2% |
| Q1 FY2023 | Mar 31, 2023 | $51.38M | +25.6% |
| Q4 FY2022 | Dec 31, 2022 | $46.23M | +7.9% |
| Q3 FY2022 | Sep 30, 2022 | $54.26M | +48.4% |
| Q2 FY2022 | Jun 30, 2022 | $48.83M | +41.4% |
| Q1 FY2022 | Mar 31, 2022 | $40.92M | +34.7% |
| Q4 FY2021 | Dec 31, 2021 | $42.84M | +40.2% |
| Q3 FY2021 | Sep 30, 2021 | $36.57M | +10.8% |
| Q2 FY2021 | Jun 30, 2021 | $34.53M | +6.1% |
| Q1 FY2021 | Mar 31, 2021 | $30.37M | +6.9% |
| Q4 FY2020 | Dec 31, 2020 | $30.55M | -17.4% |
| Q3 FY2020 | Sep 30, 2020 | $33.02M | +1.8% |
| Q2 FY2020 | Jun 30, 2020 | $32.55M | +29.9% |
| Q1 FY2020 | Mar 31, 2020 | $28.42M | +60.1% |
| Q4 FY2019 | Dec 31, 2019 | $37.00M | +399.2% |
| Q3 FY2019 | Sep 30, 2019 | $32.45M | – |
| Q2 FY2019 | Jun 30, 2019 | $25.05M | – |
| Q1 FY2019 | Mar 31, 2019 | $17.75M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.41M | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?